
Anti-Ro/SSA antibodies are an independent risk factor for interstitial lung disease in patients with systemic sclerosis, but do not predict disease progression or survival.


coremsg

Anti-Ro/SSA antibodies predicted which patients were at most risk for ILD but not ILD progression or overall disease progression and death.

Anti-Ro/SSA Antibodies Have Potential to Predict ILD in SSc

anti-ro-ssa-antibodies-linked-to-higher-risk-of-interstitial-lung-disease-in-systemic-sclerosis-patients


Anti-Ro/SSA Antibodies Linked to Higher Risk of Interstitial Lung Disease in Systemic Sclerosis Patients
